You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Immunotherapy in Non-Small Cell Lung Cancer

  • Authors: Charu Aggarwal, MD, MPH (Session Chair); Marina Chiara Garassino, MD; Deborah Doroshow, MD, PhD; Puneeth Iyengar, MD, PhD
  • CME / ABIM MOC / CE Released: 3/31/2023
  • Valid for credit through: 3/31/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.75 ABIM MOC points

    Nurses - 0.75 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    Pharmacists - 0.75 Knowledge-based ACPE (0.075 CEUs)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, pulmonologists, pathologists, radiologists, surgeons, primary care physicians (PCPs), critical care specialists, internal medicine specialists, emergency medicine physicians, nurses/nurse practitioners (NPs), physician assistants (PAs), and pharmacists involved in the care of patients with or at risk for lung cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or malignant pleural mesothelioma (MPM).

The goal of this activity is for the learner to be better able to discuss the management of patients using immunotherapy.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial data evaluating immunotherapy as treatment for patients with NSCLC
    • Optimal approaches to oligometastatic disease
  • Have greater competence related to
    • Selecting the most appropriate immunotherapy-containing regimen for a patient with NSCLC
  • Demonstrate greater confidence in their ability to
    • Communicate treatment considerations with a multidisciplinary team


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


  • Charu Aggarwal, MD, MPH

    Leslye M. Heisler Associate Professor of Lung Cancer Excellence  
    Director, Precision Oncology Innovation, Penn Center for Cancer Care Innovation (PC3I)  
    Associate Director, Penn Center for Precision Medicine Physician Leader, Airways Malignancies Clinical Research   
    University of Pennsylvania  
    Philadelphia, Pennsylvania 


    Charu Aggarwal, MD, MPH, has the following relevant financial relationships:  
    Consultant or advisor for: AstraZeneca; BeiGene (Beijing) Co., Ltd; Blueprint Genetics; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo, Inc.; Eisai, Inc.; Genentech; Janssen; Lilly; Merck; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; Shionogi & Co., Ltd.; Turning Point Therapeutics 
    Research funding from: AstraZeneca; Genentech; Incyte Corporation; Macrogenics; MedImmune Inc.; Merck Sharp & Dohme; Roche

  • Marina Chiara Garassino, MD

    Professor of Medicine 
    Hematology and Oncology 
    Department of Medicine 
    University of Chicago 
    Chicago, Illinois 


    Marina Chiara Garassino, MD, has no relevant financial relationships.

  • Deborah Doroshow, MD, PhD

    Assistant Professor 
    Thoracic Oncology | Novel Therapeutics 
    Tisch Cancer Institute 
    Icahn School of Medicine at Mount Sinai 
    New York, New York 


    Deborah Doroshow, MD, PhD, has the following relevant financial relationships: 
    Consultant or advisor for: AstraZeneca (former); Dedham Group; Mirati Therapeutics, Inc. (former)

  • Puneeth Iyengar, MD, PhD

    Associate Professor 
    The University of Texas Southwestern Medical Center 
    Chief of Lung Radiation Oncology Service 
    Vice Chair, Strategy & Program Development 
    Dallas, Texas 


    Puneeth Iyengar, MD, PhD, has the following relevant financial relationships: 
    Consultant or advisor for: AstraZeneca 
    Research funding from: Incyte Corporation 


  • Megan Cannon, PhD

    Medical Education Director, WebMD Global, LLC


    Megan Cannon, PhD, has no relevant financial relationships.

  • John Churchwell, PhD

    Medical Education Director, Medscape, LLC 


    John Churchwell, PhD, has the following relevant financial relationships:
    Formerly employed by an ineligible company: Medtronic, Inc.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.75 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for ​0.75​ contact hour(s) (​0.075​ CEUs) (Universal Activity Number: ​JA0007105-0000-23-083-H01-P​).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Immunotherapy in Non-Small Cell Lung Cancer

Authors: Charu Aggarwal, MD, MPH (Session Chair); Marina Chiara Garassino, MD; Deborah Doroshow, MD, PhD; Puneeth Iyengar, MD, PhDFaculty and Disclosures

CME / ABIM MOC / CE Released: 3/31/2023

Valid for credit through: 3/31/2024, 11:59 PM EST


Contents of This CME Activity

All sections of this activity are required for credit.

Monotherapy, Doublet, Triplet, or Quadruplet?: Frontline Management of Patients With NSCLC in the Absence of a Driver Mutation

Hear the latest on frontline management of NSCLC from a leader in the field.
Marina Chiara Garassino, MD

Is Immunotherapy Still a Viable Option in a Second-Line NSCLC?

Are you considering immunotherapy as a second-line option? Consider the alternatives with this timely discussion.
Deborah Doroshow, MD, PhD

Management of Patients With Oligometastatic Disease in the Era of Immunotherapy

Enhance your armamentarium of healthcare capabilities by considering management of oligometastatic disease in the era of immunotherapy.
Puneeth Iyengar, MD, PhD

Learning Feedback Questions

Please answer these questions to complement your learning experience.

  • Print